Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application by Goeree, Ron et al.
© 2011 Goeree et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
ClinicoEconomics and Outcomes Research 2011:3 89–104
ClinicoEconomics and Outcomes Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
89
REviEw
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CEOR.S14404
Transferability of health technology assessments 
and economic evaluations: a systematic review  
of approaches for assessment and application
Ron Goeree1,2
Jing He1,2
Daria O’Reilly1,2
Jean-Eric Tarride1,2
Feng Xie1,2
Morgan Lim1,2
Natasha Burke1,2
1Programs for Assessment of 
Technology in Health (PATH) 
Research institute, St Joseph’s 
Healthcare Hamilton, ON, Canada; 
2Department of Clinical Epidemiology 
and Biostatistics, McMaster University, 
Hamilton, ON, Canada
Correspondence: Ron Goeree 
Programs for the Assessment of 
Technology in Health (PATH) Research 
institute, 25 Main St w, Suite 2000, 
Hamilton, ON L8P 1H1, Canada 
Tel +1 905 523 7284 ext 5266 
Fax +1 905 522 0568 
Email goereer@mcmaster.ca
Background: Health technology assessments (HTA) generally, and economic evaluations 
(EE) more specifically, have become an integral part of health care decision making around the 
world. However, these assessments are time consuming and expensive to conduct.   Evaluation 
resources are scarce and therefore priorities need to be set for these assessments and the ability 
to use information from one country or region in another (geographic transferability) is an 
increasingly important consideration.
Objectives: To review the existing approaches, systems, and tools for assessing the geographic 
transferability potential or guiding the conduct of transferring HTAs and EEs.
Methods: A systematic literature review was conducted of several databases, supplemented 
with web searching, hand searching of journals, and bibliographic searching of identified 
articles. Systems, tools, checklists, and flow charts to assess, evaluate, or guide the conduct of 
transferability of HTAs and EEs were identified.
Results: Of 282 references identified, 27 articles were reviewed in full text and of these, 
seven proposed unique systems, tools, checklists, or flow charts specifically for geographic 
transferability. All of the seven articles identified a checklist of transferability factors to 
consider, and most articles identified a subset of ‘critical’ factors for assessing transferability 
potential. Most of these critical factors related to study quality, transparency of methods, the 
level of reporting of methods and results, and the applicability of the treatment comparators to 
the target country. Some authors proposed a sequenced flow chart type approach, while others 
proposed an assessment of critical criteria first, followed by an assessment of other noncritical 
factors. Finally some authors proposed a quantitative score or index to measure transferability 
potential.
Conclusion: Despite a number of publications on the topic, the proposed approaches and the 
factors used for assessing geographic transferability potential have varied substantially across 
the papers reviewed. Most promising is the identification of an extensive checklist of critical 
and noncritical factors in determining transferability potential, which may form the basis for 
consensus of a future tool. Due to the complexities of identifying appropriate weights for each 
of the noncritical factors, it is still uncertain whether the assessment and calculation of an 
overall transferability score or index will be practical or useful for transferability considerations 
in the future.
Keywords: costs and cost analysis, economic evaluation, health technology assessment, 
geographic transferability, portability, generalizability
Introduction
Over the past two decades, decision-makers at all levels of the health care system 
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care resources. As a result, public and private agencies 
worldwide have turned to evidence-based processes to 
  better assess the clinical and economic benefits of both new 
and existing health care technologies. Although safety and 
efficacy are essential first considerations, health technology 
  assessment (HTA), in general, and economic evaluation 
(EE),   specifically, have become an integral component of the 
overall decision-making process regarding the assessment and 
adoption of both new and existing health care   technologies. 
Full EE, whether conducted alongside a trial or as a modeling 
study, assesses both the costs and consequences of a health 
care intervention, which is evaluated in comparison to at 
least one other intervention. The general rule when assessing 
programs is that the difference in costs is compared to the 
difference in outcomes achieved, typically in an incremental 
analysis. Therefore, the basic tasks of economic evaluation 
are to identify, measure, value, and compare the costs and 
consequences of the alternatives under consideration.1
The basic types of economic evaluation include cost-
benefit analysis (CBA), cost-effectiveness analysis (CEA), 
and cost-utility analysis (CUA). CBA measures and values 
the benefits and costs of outcomes achieved from a program 
or intervention in monetary terms. For example a CBA may 
require that a dollar value be placed on expected years of life 
gained or expected improvements in health and wellbeing. 
The benefits and costs that are counted include not only those 
directly attributed to the program or intervention but also any 
indirect benefits or costs through externalities or other third-
party effects.2 However, much of the controversy surrounding 
the use of CBA derives from the fact that consumers of health 
care are not used to valuing health outcomes and these other 
intangible benefits. Given these difficulties, CEA provides 
a more practical approach to health care decision-making. 
It compares the costs of achieving particular health effects 
that are measured in natural units related to the objective 
of the program, such as average cases of disease avoided, 
or years of life gained. The results of such comparisons 
are stated in terms of cost per unit of effect. CUA is often 
seen as a special form of CEA that introduces measures of 
benefits that reflect individuals’ preferences over the health 
consequences of alternative programs that affect them. CUAs 
use a global measure of health outcome, such as quality-
adjusted life-years (QALYs) by undertaking one program 
instead of another, and the results are often expressed as 
a cost per QALY gained.1 This enables the comparison of 
different types of programs, which makes CUA more prac-
tical for decision-makers. Sometimes a cost-minimization 
analysis (CMA) may be performed if the alternatives under 
consideration are considered to achieve the given outcomes 
to the same extent. However, CMA is usually not viewed 
as a separate form of full economic evaluation because the 
original intent of the study was to conduct either a CEA 
or CUA.1
Approaches to conducting full economic analyses can be 
categorized as either trial-based studies using patient-level 
data or decision analytic modeling based on secondary data. 
Given that randomized clinical trials are typically a necessary 
condition for the successful licensing of a pharmaceutical, 
economic data are sometimes collected by piggybacking onto 
the same trials. This approach is potentially more attractive 
for internal validity, while the main limitation is that this 
study may suffer from external generalizability. Decision 
analytic modeling brings together a range of evidence sources 
and allows the expansion of the comparators considered in 
the analysis and an expansion of the time horizon beyond 
the trial period. In addition, decision analytic modeling 
provides a framework for informing specific decision-
making under conditions of uncertainty by allowing more 
convenient assessment of modeling assumptions, modeling 
structural uncertainty, and different patient subgroups 
(heterogeneity).1
These evaluations, either done as a trial or modeling study 
and either as an EE or as part of a broader HTA report, are 
usually time-consuming, expensive, and demanding in terms 
of statistical sophistication and in terms of the researchers 
equipped with the necessary skills. As a result, it is not 
possible to conduct an EE or HTA on every intervention. 
Fortunately, health care decision-makers often have access 
to previously published EEs or HTAs on the topic of interest. 
Unfortunately, it is commonly the case that these EEs or 
HTAs are from another jurisdiction and decision-makers 
need to assess whether, and to what extent, the assessment 
and analysis from this other jurisdiction applies to their own 
jurisdiction. Several terms such as geographic transferability, 
generalizability, portability, and extrapolation have been used 
to describe the process of applying the analyses and results 
of EEs or HTAs from one jurisdiction to another jurisdiction. 
Before considering conducting an EE or HTA for the 
jurisdiction of interest, it is important to first consider whether 
an EE or HTA on the topic of interest may already exist from 
another jurisdiction, and if so, the potential applicability of 
transferring or using these results for the country of interest. 
This is especially useful for decision-makers who face budget 
or time constraints in health care resource allocation decisions 
and given the increasing number of technologies that need 
to be assessed. As a result of the growing demand in many ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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jurisdictions to use evidence as part of their decision-making 
process, there is growing interest in the assessment of trans-
ferability of EEs and HTAs, with the aim to decide the extent 
to which the results of a study from another jurisdiction can 
be adapted locally.
There have been a series of important contributions to 
the published literature in recent years addressing the issue 
of geographic transferability of EE and HTA results. Several 
efforts were made to identify potential factors causing 
variability in EE and HTA data between locations. One of 
the first researchers who helped to progress the debate about 
transferability was O’Brien,3 who identified six threats 
to the transferability of economic data across countries. 
Since then the list of the factors affecting transferability 
has been further expanded through a number of review 
papers on the topic. For example, in a systematic review by 
Goeree4 a comprehensive classification system was devel-
oped of over 80 factors grouped into 5 broad categories of 
variability factors including characteristics of the patient, 
the disease, the health care provider, and the health care 
system. In addition to factors which may raise transfer-
ability concerns, authors have proposed systems, checklists 
or even indices to assess or measure the transferability 
potential of EEs and HTAs conducted in other jurisdictions 
to the jurisdiction of interest. However, no previous study 
has summarized these papers. Therefore, the purpose 
of this study was to review and summarize the existing 
approaches, systems, and tools for assessing transferability 
potential or guiding the actual conduct of transferability of 
HTAs and EEs.
Methods
Literature search strategy
Targeted literature search strategies were developed for 
PubMed, Ovid MEDLINE, and EMBASE databases 
respectively. Detailed search terms are provided in the 
Appendix. The search focused on relevant papers reflecting 
the methods, systems, or tools used to assess transferability 
or generalizability of economic evaluation results across 
jurisdictions. Studies published in English were considered, 
without publication year restriction. The literature search 
was supplemented with online searching using the Google 
search engine, hand searching of relevant journals, and 
reviewing of the bibliographies of identified articles. The 
search was run on 22 November 2010. All references 
obtained were incorporated into a reference manager 
database to check for duplication and to perform title and 
abstract screening.
Literature selection criteria
Studies meeting our selection criteria were those that had 
a focus on methods or tools applied to assess or evaluate 
transferability. The tools could consist of a checklist, 
toolkit, system, practice guideline, set of criteria, decision 
chart, or index. Articles were excluded if they were general 
  narrative reviews, if they focused on identification of sources 
of variability in EEs of HTAs or factors likely to affect 
transferability between locations, or if they addressed the 
analytical approaches of adapting cost-effectiveness results 
to a particular jurisdiction of interest.
Synthesis and reporting
It was determined ‘a priori’ that due to the nature of 
the different proposed systems, a quantitative summary 
(eg, meta-analysis) of retrieved studies was not feasible. 
As a result, each paper is presented sequentially by year 
of publication with a qualitative description of the tool, 
checklist, criteria, system, or flow chart. Generalizations and 
conclusions across these approaches are provided following 
a description of each approach.
Results
In total, the comprehensive search identified 282 citations. 
Among them, 230 articles were identified from PubMed, and 
52 additional articles were identified from Ovid MEDLINE 
and EMBASE. A Google search did not identify any 
additional citations. Title and abstract screening was carried 
out for relevance to the topic and resulted in the inclusion of 
23 articles, which were retrieved in full text and reviewed 
in detail. Four additional references were identified during 
bibliography searching. Among the 27 articles reviewed in 
full text, seven papers with specific focus on approaches to 
assess the transferability of economic evaluations across 
geographic locations were included in the review. Please 
refer to Figure 1 for a flow diagram of study selection. 
A description of the system or approach from each of the 
seven papers, by year of publication, is provided below along 
with a summary of the application of system or approach if 
available.
Heyland’s generalizability criteria (1996)
Heyland5 introduced a list of criteria when assessing the 
generalizability of economic evaluations to their own setting 
in order to improve the efficiency of their critical care unit. 
The criteria were based on ten key variability factor-based 
questions regarding clinical generalizability and health care 
system generalizability (see Table 1). Before applying these ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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criteria, selected studies also need to meet the inclusion 
criteria for minimal methodologic standard, which includes 
a comprehensive description of competing alternatives, 
sufficient evidence of clinical effectiveness or efficacy, 
appropriate identification, measurement and valuation of 
all important costs, and appropriate sensitivity analysis that 
takes into account all estimates of uncertainty.
The authors identified 29 critical care studies (19 CEAs, 
6 CMAs, 4 partial economic evaluations that only compared 
costs of alternative interventions) that met the minimum 
level of methodological rigor to be further evaluated 
for generalizability to their own intensive care unit in a 
tertiary care hospital in Hamilton, ON. Of the 29 studies, 
14   adequately described both competing alternatives; 17 
provided sufficient evidence of clinical effectiveness; and 
six identified, measured, and evaluated costs appropriately. 
Overall, it was determined that none of the 29 papers met 
the minimum methodological standard for all criteria. Four 
papers that provided adequate costs and clinical   effectiveness/
efficacy were further evaluated using the proposed generaliz-
ability criteria from a hospital perspective. Overall, it was 
found that the differences in costing methods precluded the 
generalizability of three of these studies; however, for two 
of them, the direction or qualitative result was probably 
generalizable, whereas the magnitude or quantitative result 
was not.
Späth’s transferability indicators (1999)
Späth6 defined five indicators to assess the eligibility of 
economic evaluations for transfer to a given health care 
system (see Table 2). Similar to the approach proposed by 
Heyland,5 before applying the transferability criteria, Späth 
proposed four criteria critical for internal methodological 
validity (ie, perspective of the study from national level, 
comparison of two or more options, description of the 
evaluated therapies, and the assessed therapies and/or its 
comparators are used in the health system of interest) that 
need to be satisfied before consideration of transferability 
indicators. Studies fulfilling the four critical criteria are 
then assessed for eligibility for transferability using a 
five-indicator checklist. The five indicators comprise three 
dimensions including the settings at local level (potential 
282 records identified
from database search 
259 references excluded after
title and abstract screening, 
with reasons: 
No mention of transferability
or generalizability
Pure economic evaluations
Review of cost-effectiveness
analysis
23 potentially relevant
publications retrieved for 
further scrutiny as full
text
20 reports excluded, with
reasons:
Narrative reviews 
Focused on causes/factors
of variability 
Focused on analytical 
approaches to generating
country-specific CE results
7 articles selected for
final systematic review
4 additional articles identified
through bibliography review
and hand search •
•
•
•
•
•
Figure 1 Flow diagram of literature selection for systematic review.
Abbreviation: CE, cost effectiveness.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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users of the economic evaluation and characteristics of the 
patient population) in which the studies might be used, the 
transferability of health outcome data, and the transferability 
of resource utilization data (health care resources used and 
their unit prices). Studies from other health systems and 
settings must fulfill all of the five indicators in order to be 
considered transferable.
To test the proposed checklist, 26 published economic 
evaluations regarding adjuvant therapy in women with 
breast cancer were identified to apply to the French health 
care system. Six of these studies met the critical appraisal 
of internal validity to be assessed further for transferability. 
These studies covered different types of economic evaluation 
(4 CUA, 1 CEA, 1 CMA; 3 decision analyses, and 3 clinical 
trial results with cost estimations). All of the evaluations 
included direct medical costs, but no other types of resource 
utilization information were included in the studies and the 
related unit prices were not reported. Therefore, none of 
the six studies were determined to be eligible for transfer to 
the French health care system.
welte’s transferability decision  
chart (2004)
One of the best known transferability assessment tools was 
published by Welte7 a few years later. As shown in Figure 2, 
Welte proposed the use of a transferability decision chart 
that takes into account ‘knock-out’ criteria, a transferability 
checklist, and methods for improving transferability and for 
assessing the uncertainty of transferred results. The decision 
chart starts with general ‘knock-out’ criteria to identify 
studies that are deemed not transferable. These general 
‘knock-out’ criteria include:
•	 The relevant technology is not comparable to the one that 
shall be used in the decision country.
•	 The comparator is not comparable to the one that is 
relevant to the decision country.
•	 The study does not possess an acceptable quality.
If the general ‘knock-out’ criteria have been passed, a 
transferability checklist is then applied to test for specific 
‘knock-out’ criteria and to determine whether modeling 
adjustments are necessary. The checklist is based on 14 factors 
of methodological, health care system and population 
characteristics. Although not a general ‘knock-out’ criteria, 
each relevant transferability factor from the checklist can 
become a specific ‘knock-out’ criterion if the factor/criterion 
cannot be assessed because of lack of data from the study or 
the decision country. The specific criteria checklist is listed 
below:
•	 Perspective
•	 Discount rate
•	 Medical cost approach
•	 Productivity cost approach
•	 Absolute and relative prices in health care
•	 Practice variation
•	 Technology availability
•	 Disease incidence/prevalence
•	 Case-mix
•	 Life expectancy
•	 Health-status preference
•	 Acceptance, compliance, incentives to patients
•	 Productivity and work-loss time
•	 Disease spread
For each transferability factor, it has to be determined 
1) to what extent it is relevant for the investigated technology; 
Table 1 Heyland’s generalizability criteria
Clinical generalizability
1.   Are the patients described in the analysis similar to those patients you 
see in your own setting?
Systems generalizability
1.   is the viewpoint of the analysis relevant to your clinical setting/
situation?
2.   is the intervention under study generalizable to your setting? (ie, 
despite good clinical evidence, is such a program available or likely  
to be available in your setting?)
3.   Are the costing methods applicable to the health care system in which 
you work?
    i) is the unit price for drugs, physician fees, laboratory tests, etc the same?
   ii) is the mix of resources consumed the same?
  iii)   is the volume of patients, and therefore, the average cost per 
patient, similar across systems?
  iv) Can you convert exchange rates across countries appropriately?
4. Are the outcomes measured appropriate to your setting?
  i)   was a method to measure the outcomes compatible with the 
current methods utilized in your setting?
  ii)   if a preference-based measure was used, is there evidence that  
the preferences of your patients are the same as those preferences 
used in the analysis?
5. is the discount rate applicable to your setting?
Source: Heyland DK, et al. Crit Care Med. 1996;24(9):15.
Table 2 Späth’s transferability indicators
1. The setting(s) in which the studies might be used:
	•  Potential users
	•  Characteristics of the treated patient population
2. The transferability of health outcome data:
	•  Health outcome data
3. The transferability of resource utilization: 
	•  Health-care resources
	•  Unit prices of health-care resources and discount rates
Source: Späth HM, et al. Health Policy. 1999;49:165–166.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
94
Goeree et al
2) the correspondence between the study country and the 
decision country; and 3) the likely effect of the transferability 
factor on the results.
If any of the general or specific criteria applies, then users 
should examine the transferability of the study design rather 
than the study results. For studies that pass all the ‘knock-out’ 
criteria, the need for modeling-based adjustment to improve 
transferability will be evaluated based on data availability. 
For studies in which modeling adjustments are necessary, the 
decision chart will also guide the user to identify whether 
the study results are transferable after adjustments either in 
a descriptive way (reapply the decision chart) or by doing 
probabilistic or multivariate sensitivity analysis.
The transferability decision chart was then applied to 
several international cost-effectiveness studies in the areas 
of interventional cardiology, vaccination, and screening. 
Application of the transferability checklist to an American 
multicenter study of stenting versus percutaneous translu-
minal coronary angioplasty (PTCA) by Cohen8 revealed 
that modeling adjustments would be necessary for the 
German Ministry of Health, however, because resource 
valuation was not presented in enough detail, the results 
of this study could not be transferred. Another Belgium 
Netherlands Stent Study by Serruys9 also showed that 
modeling adjustments were needed for Germany. The study 
presented sufficient details, which enabled the adjustment 
of resource valuation using data derived from the German 
study. The adjusted study results were then evaluated for 
transferability by applying the transferability checklist 
again, and the authors concluded that transferring the order 
of magnitude of the adjusted EE result seemed defendable, 
but not the exact value. The third case was an example 
where Denmark was interested in a Dutch EE that used 
a dynamic model instead of the common static decision-
analysis model to project the cost effectiveness of a large-
scale chlamydial screening program. General ‘knock-out’ 
criteria were fulfilled and the transferability of the study 
model was   examined. Although it was found that transfer-
ring the economic model was laborious, it was determined 
that the progression component of the disease model and 
the productivity cost module could easily be transferred. 
Because these models take much more time to build than to 
adjust from other contexts, it was estimated that transferring 
the model saved approximately 6 years of work.
General knock-out criterion fulfilled?
Apply checklist
NO YES
Study results not transferable
Specific knock- out criterion fulfilled?
If NO, assess whether modeling
adjustments necessary
If YES, study results not 
transferable. Go to A
Study results fully
transferable
B Study results qualitatively
transferable*
Study data/methods
complete? If higher transferability
required, go to B
If NO, study results
not transferable.Go to A
If YES, relevant decision
country data available?
Fully available Partially available Not available
Access variability of parameters + perform
probabilistic or multivariate sensitivity
analysis
Substitute available parameters. Calculate
new CER
Substitute all parameters. Calculate new
CER
Adjusted study results fully transferable Re-apply
checklist
Assess variability of non-substituted parameters + 
perform probabilistic or multivariate sensitivity analysis
Study results qualitatively
transferable*
Study results not transferable. 
Go to A
C Go to C
Adjusted study results 
qualitatively transferable*
Adjusted study results not
transferable. Go to A
A
Assess transferability of study 
(sub) model or design
Not necessary Necessary
Figure 2 welte’s transferability decision chart.
Note: *indicates order of magnitude can be transferred.
Source: welte R, et al. Pharmacoeconomics. 2004;22(13):863.
Abbreviation: CER, cost-effectiveness analysis ratio.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Boulenger’s transferability information 
checklist (2005)
In the article by Boulenger,10 the authors developed a transfer-
ability information checklist and used it to generate a score 
that represents the percentage of applicable items that were 
either adequately or partially addressed in economic studies. 
The checklist is shown in Table 3. The overall checklist 
comprises 42 questions and includes two parts: the first part is 
related to overall methodological quality and internal validity 
of the studies; the second part (transferability sub-checklist) 
contains 16 items that are more specifically focused on 
judging the transferability of a study. The extended checklist 
Table 3 Boulenger’s transferability information checklist
Each question is answered with ‘yes’, ‘partially’, ‘no/no information provided’ or ‘not applicable’
Q1 is the study question clearly stated
Q2 Are the alternative technologies justified by the author(s)?
HT1a Is the intervention described in sufficient detail?
HT2a Is (are) the comparator(s) described in sufficient details?
SE1 Did the authors correctly specify the setting in which the study took place (eg, primary care, community)?
SE2a Is (are) the country(ies) in which the economic study took place clearly specified?
P1a Did the authors correctly state which perspective they adopted for the economic analysis?
SP1a is the target population of the health technology clearly stated by the authors or when it is not done can it be inferred  
by reading the article?
SP2 Are the population characteristics described? (eg, age, sex, health status, socio-economic status, inclusion/exclusion criteria)
SP3a Does the article provide sufficient detail about the study sample(s)?
SP4 Does the paper provide sufficient information to assess the representativeness of the study sample with respect to the 
target population?
M1 if a model is used, is it described in detail?
M2 Are the origins of the parameters used in the model given?
E1 if a single study is used, is the study design described (sample selection, study design, allocation, follow-up)?
E2 if a single study is used, are the methods of data analysis described (iTT/per protocol or observational data)?
E3 if based on a review/synthesis of previous published studies, are review methods described (search strategy, inclusion 
criteria, sources, judgment criteria, combination, investigation of differences)?
E4 if based on opinion, are the methods used to derive estimates described?
E5a Have the principal estimates of effectiveness measure been reported?
E6 Are the side effects or adverse effects addressed in the analysis?
E7a Does the article provide the results of a statistical analysis of the effectiveness results?
B1 Do the authors specify any summary benefit measure(s) used in the economic analysis?
B2 Do the authors report the basic method of valuation of health states or interventions?
B3 Do the authors specify the source(s) of health states (eg, specific patient populations or the general public)?
B4 Do the authors specify the valuation tool used?
B5a Is the level of reporting of benefit data adequate (incremental analysis, statistical analyses)?
C1a Are the cost components/items used in the economic analysis presented?
C2 Are the methods used to measure cost components/items provided?
C3 Are the sources of resource consumption data provided?
C4 Are the sources of unit price data provided?
C5a Are the unit prices for resources given?
C6a Are costs and quantities reported separately?
C7a is the price year given?
C8 is the time horizon given for each element of the cost analysis?
C9a is the currency unit reported?
C10 is a currency conversion rate given?
C11 Does the article provide the results of a statistical analysis of cost results?
D1 Was the summary benefit measure(s) discounted?
D2 were the cost data discounted?
D3 Do the authors specify the rate(s) used in discounting costs and benefits?
D4 were discounted and not discounted results reported?
S1a Are quantitative and/or descriptive analysis conducted to explore variability from place to place?
O1a Did the authors discuss caveats regarding the generalizability of their results?
Note: aitems comprising the transferability sub-checklist.
Source: Boulenger S, et al. Eur J Health Econom. 2005;4:337–338.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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was divided into six main sections: the subject and key 
elements of the study (Q1-M2), characteristics of the methods 
used to measure clinical outcomes (E1-E7), the measure of 
health benefits used in the economic analysis (B1-B5), the 
costs (C1-C11), discounting (D1-D4), and discussion by the 
authors (S1, O1). To quantitatively evaluate how thoroughly 
key methodological items regarding transferability are 
addressed and reported in each study, a percentage score of 
transferability information can be derived for both the full 
checklist and the sub-checklist after assigning each item 
one of the following values: 1 for ‘yes’, 0.5 for ‘partially’, 
and 0 for ‘no/no information’.11 Based on the responses for 
each item in the checklist, Boulenger generated an overall 
transferability score based on the assumption that each item 
or factor contributes equal weight to the overall score. In 
Boulenger’s system, there are no critical criteria as each 
criterion contributes equally to the overall score.
The checklist was applied to 25 studies to assess the level 
of transferability of EEs of health care programs between the 
UK and France. Selected studies included 17 multi-country 
studies that included study sites in France and the UK, 
along with eight single-country studies from France or the 
UK, which evaluated the same health technology using the 
same methodology. Cost and/or cost-effectiveness ratios in 
these studies were converted using purchasing power parities 
(PPP), with the Euro as the common currency. These enabled 
comparisons of the results between the two countries. The 
mean percentage transferability information score for the full 
checklist was 66.9% ± 13.6%, and the results obtained for 
the sub-checklist (68.8% ± 15.1%) were very similar to the 
full-checklist, suggesting a high correlation between overall 
study quality and a good transferability score. The potential 
relationship between the transferability information score 
and the characteristics of the study (multi-country vs single-
country) was explored using χ2 test; however, no statistically 
significant differences were found. Comparisons for the 25 
economic evaluations revealed that in the vast majority of 
cases, the cost-effectiveness ratio for France was more favor-
able than that of the UK. Therefore, the authors pointed out 
that if this finding was confirmed by further studies, the impli-
cation would be that a decision-maker in France, on seeing 
a study performed in the UK, could be fairly confident that 
even more favorable results would be obtained for France. 
However, it is difficult to determine the extent to which the 
results would be more favorable due to the wide range of 
difference (1.5%–250%). For the 17 multi-country studies, 
five enabled direct comparisons, and the source of difference 
was merely a price effect (unit costs).
Drummond’s application algorithm (2009)
An International Society of Pharmacoeconomics and 
Outcomes Research (ISPOR) Task Force on Good Research 
Practices lead by Drummond,12 proposed a 4-step application 
algorithm that determines the appropriate methods for adjust-
ing cost-effectiveness estimates based on data   availability. 
The authors considered three types of situations where 
cost-effectiveness results are not transferable or in other 
words there are three critical criteria: 1) if either the experi-
mental technology or the comparator(s) are not relevant in 
the jurisdiction of interest; 2) if the methodological quality of 
the studies doesn’t meet local standards, which is similar to 
Welte’s general ‘knock-out’ criteria; 3) if the study population 
is different between jurisdictions. Furthermore, they developed 
an application algorithm (see Figure 3) to assess whether the 
study results are directly transferable through simple adjust-
ment procedures for practice variations, unit health care costs, 
the settings, time horizon, discount rates, and productivity/time 
costs (ie, similar to Welte’s specific ‘knock-out’ criteria), or 
whether more elaborate adjustment is needed which analyzes 
individual patient data or uses decision-analytic modeling 
techniques depending on whether the jurisdiction of interest 
is within a multi-location study that has been conducted. The 
authors further addressed analytical methods of using trial-
based patient data, and under what circumstances decision-
analytic models should be considered.
Turner’s transferability checklist (2009)
The next system proposed was by Turner13 as part of the 
European network for Health Technology Assessment 
CE information
available? 
Relevant to the decision
problem and sound 
methodology? 
(See Welte et al criteria)7 
Consider
other data 
and
modeling  
Consider
other data 
and
modeling  
CE reported for
comparable 
treatment patterns? 
Simple adaptation, eg,
using an appropriate 
price vector  
CE based on multi-location trial.
Data from the jurisdiction
included?
Consider analysis
of individual
patient data 
Consider other
data and 
modeling  
Yes No
Yes No
Yes No
Yes No
Figure 3 Drummond’s steps for determining appropriate methods for adjusting 
cost-effectiveness information.
Source: Drummond MF, et al. Value Health. 2009;12:411.
Abbreviation: CE, cost effectiveness.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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(EUnetHTA) project.14 These authors and contributors 
developed an adaptation toolkit that contains a series of 
checklists, questions, and resources to guide the users through 
the process of selecting possible relevant material, assessing 
the relevance, reliability, and transferability of HTA reports 
from other settings or jurisdictions, and adapting the informa-
tion for the desired context of their own setting. The toolkit is 
structured into two sections: 1) speedy sifting – a screening 
tool which enables rapid screening of existing HTA reports 
to assess the relevance of the HTA report for adaptation; 
2) main toolkit – a more comprehensive tool with questions 
on reliability and issues regarding transferability. The speedy 
sifting section contains eight questions:
1.  Are the policy and research questions being addressed 
relevant to your questions? (Yes/No)
2.  What is the language of this HTA report? Is it possible 
to translate this report into your language? (Yes/No)
3.  Is there a description of the health technology being 
assessed? (Judgment needed)
4.  Is the scope of the assessment specified? (Judgment 
needed)
5.  Has the report been externally reviewed? (Judgment 
needed)
6.  Is there any conflict of interest? (Judgment needed)
7.  When was the work that underpins this report done? Does 
this make it out of date for your purposes? (Judgment 
needed)
8.  Have the methods of the assessment been described in 
the HTA report? (Judgment needed)
Users are supposed to undertake the speedy sifting for a 
quick assessment of the relevance of the report for adaptation 
before using the more comprehensive tool. Based on answers 
to the eight questions, users can make their own judgment on 
whether to: 1) proceed to the main part of the toolkit, 2) seek 
further information, or 3) end the adaptation process and 
consider creating a new local HTA report. To that extent, 
these first eight questions are similar to critical criteria 
proposed in early systems.
The main part of the toolkit (see Table 4) comprises 
five domains in the form of a checklist: technology use, 
safety, effectiveness or efficacy, economic evaluation, and 
organizational aspects. Each of the domains includes a 
series of questions that enable the assessment of a report’s 
reliability, specific relevance, and transferability. Answers to 
these questions help the users extract information from the 
corresponding sections of the HTA report, and incorporate 
it within an HTA report in their own setting. There may 
be a need to update the data and supplement with local 
context data. The main toolkit can be used in its entirety in 
all five domains or can be used to adapt information in one 
or more domains. If after going through the main toolkit it 
is found that no part of the HTA report was reliable and/or 
transferable, then users should not consider transferability 
and should consider creating a new local HTA report.
Antonanzas’ transferability index (2009)
And finally, in the paper by Antonanzas,15 the authors have 
constructed a numerical global transferability index based 
on weighted objective and subjective elements to measure 
the degree of transferability of EE results. The global 
index was derived through a mathematical formula that 
combines factors and weights from a general index and a 
specific index. Both of the partial indices considered a range 
of critical and noncritical factors that are similar to those 
considered by Boulenger10 and Welte.7 The factors used in 
the general and specific indices are shown in Table 5 and the 
index formulas are shown in Figure 4. In the first phase of 
this system, a general transferability index considers seven 
critical objective values and then the same 16 noncritical 
objective factors as proposed by Boulenger10 (see Table 5). 
The formula for the general index (IT1) is shown in the 
first panel of Figure 4 and is intended to initially evaluate 
the methodological quality of the studies and then exclude 
studies that are deemed not transferable. The specific index, 
which is considered subjective, measures the applicability 
of each study to the specific setting of the decision-maker. 
In the specific index there are four critical criteria and 
eight noncritical criteria. The formula for the specific 
index (IT2) is shown in the second panel of Figure 4. The 
overall global transferability index (third panel in Figure 4) 
then combines the general and specific indices, either as a 
simple or weighted arithmetic mean, the geometric mean, 
or a combination of indices. The overall approach for the 
objective factors is similar to that proposed by Boulenger,10 
however, Boulenger assumed equal weights to all noncritical 
items in that checklist. In contrast, Antonanzas derived 
weights for noncritical objective factors averaged from 
answers of seven HTA agencies in Spain and assigned these 
weights to the noncritical objective factors. The theoretical 
value of the global index is between 0 and 1, or 0 and 2, 
depending on which formulation to choose. The authors do 
not provide a threshold above which a given study would be 
deemed transferable. Given that the same study could have 
different index values in different jurisdictions, it was felt 
that health authorities from different jurisdictions should 
select the threshold value that best fits their purposes.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 4 EUnetHTA adaptation toolkit
Technology use domain
a) To assess relevance:
  1. what is the research question considered? is the research question considered within this section of the report relevant to your question?
b) To assess reliability:
  2. Were conditions, target group, relevant interventions, or comparisons between interventions and relevant outcomes appropriately defined?
  3.   is the information provided on technology use and development complete and comprehensive? Are the methods and sources used when 
elaborating the background information well documented?
  4. Are patterns of utilization, diffusion, indications, and time trends adequately described?
  5. is an analysis of the regulatory status of the technology provided (market admission, status in other countries)?
c) To assess transferability:
  6. is there any consideration of when and how technical characteristics affect outcomes?
  7.   Are there any differences in the use of this technology within the target setting (compared to the uses described in the HTA report for 
adaptation)?
Safety domain
a) To assess relevance:
  1. were harms or safety assessed?
  2. is the scope of the safety assessment relevant to your question?
b) To assess reliability:
  3. was the search for studies reasonably comprehensive?
  4.   were special sources consulted?: disease registers, data routinely collected (on utilization, costs, adverse effects …), consumer associations, etc …
The aspects that should be assessed concerning the sources of safety data are:
  5.   what are the sources of information/data? eg, surveillance databases, declaration of incidents, safety report, RCT, case reports
Quality of the safety assessment (ie, appraisal of evidence)
  6. were the criteria used for deciding which studies to include in the HTA report reported?
  7. was bias in the selection of studies avoided?
  8. Did the selection of studies (in particular the choice of eligible study designs) minimize the possibility of including studies with a high propensity for bias?
  9. were the criteria used for assessing the validity of the included studies reported?
10.   were the inclusion criteria used for the primary studies appropriate to the study questions posed by the HTA report? were the criteria used 
to assess the validity of the primary study appropriate?
11. what risks have been reported? How were these measured?
12. were the study outcomes valid? were they pertinent?
13.   Are the number of patients, their representativeness, and the quality of the data high enough to exclude a modest but clinically relevant rate of 
serious complications? ie, what is the potential for overlooking a possible serious adverse event?
14. is there a possibility for a ‘class’ effect adverse reaction or safety problem?
c) To assess transferability:
15. Does the population described for eligibility match the population to which it is targeted in the target setting?
16.   Are there any reasons to expect differences in complication rates (eg, epidemiology, genetic issues, health care system [quality of care, surveillance])?
17. Are the requirements for its use (special measures needed for use/implementation, maintenance etc) available in the target setting?
18. is the necessary expertise (knowledge and skills) available in the target setting?
19.   is safety particularly dependent on training? Are there types of teams to which the procedure should be limited for safety reasons? is there a 
need for special training or certification to deliver the intervention properly? Would it be possible (affordable) to organize such training, if any?
Effectiveness (including efficacy) domain
a) To assess relevance:
  1.   what is the research question considered? is the research question considered within this section of the HTA report relevant to your HTA 
question?
  2. Are the outcome measures relevant for your HTA question?
  3. Were the search methods used to find studies relevant to the main question(s) stated?
b) To assess reliability:
  4. was the search for studies reasonably comprehensive?
  5. were the criteria used for deciding which studies to include in the HTA report reported?
  6. was the bias in the selection of studies avoided?
  7. Did the selection of studies (in particular the choice of eligible study designs) minimize the possibility of including studies with a high propensity for bias?
  8. were the criteria used for assessing the validity of the included studies reported?
  9.   was the validity of all studies referred to in the text assessed using appropriate criteria (either in selecting studies for inclusion or in analyzing 
the studies that are cited)?
10. Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
11. Were the findings of the relevant studies combined appropriately with respect to the main question the HTA report addresses?
12. were the conclusions made by the authors supported by the data and/or analysis reported in the HTA report?
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Table 4 (Continued)
13.   How likely is it that the relevance of this HTA report has changed due to additional research that had started, completed or been published 
since this HTA report?
c) To assess transferability:
14.   would you expect the baseline risk of patients within your own setting to be the same as the baseline risk of those patients considered within 
the HTA report for adaptation? (assuming that patients receive the same treatment and same comparator)
We would expect the relative risk to be the same and baseline risk different. The user needs to consider the impact of local epidemiological and demographic 
data on the baseline risk.
Economic evaluation domain
To assess relevance and reliability:
  1. Was a well-defined question posed in an answerable form?
  2.   what is the question being asked in the report? is the economic question relevant? what type of economic analysis is being performed to 
answer the question (ie, cost-minimization, cost consequences analysis, cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis)?
  3.   Has the viewpoint or perspective for the analysis been stated clearly, along with the reasons for this choice? is it a societal perspective, third-
party payer perspective, or patient perspective? is the analysis presented in a disaggregated fashion showing these perspectives separately?
  4. was a comprehensive description of the competing alternatives given (ie, can you tell who did what to whom, where and how often)?
  5.   Has the study included a comparison of alternative treatments for patients with the same clinical condition? Are those alternatives explicitly 
stated? Are the alternatives chosen valid and reasonable?
  6.   Has the evidence of the product’s efficacy been established through randomized trials? Has the evidence of efficacy been supplemented by 
evidence of effectiveness applicable to the patient population or subgroups considered in the study? Has the latter evidence been derived from 
studies documenting routine use in clinical practice? Have all the relevant and significant variations in effectiveness for different subgroups been 
identified and reported?
  7. was the effectiveness of the programmes or services established?
  8.   Are the methods and analysis displayed in a clear and transparent manner? Are the components of the numerator (cost of each alternative) and 
denominator (clinical outcomes of each alternative) displayed? Are clinical outcomes expressed first in natural units and then translated into 
alternative units, such as benefits or utility?
  9. Are all important and relevant costs and consequences (outcomes), including adverse effects for each alternative identified?
10.   were costs and consequences measured accurately in appropriate physical units (eg, hours of nursing time, number of clinician visits, lost 
work-days, gained life-years)?
11. How is health related quality of life (HRQoL) measured?
12.   is HRQoL an important component of an economic analysis for this question? Based on the sensitivity analysis how sensitive is the estimate of 
cost-utility to variations in HRQoL?
13. were costs and consequences valued credibly?
14. were costs and consequences adjusted for differential timing?
15.   Are costs and consequences modeled (as a decision tree) with information derived from a variety of sources or estimated directly from 
specific patient population(s)?
16. Are capital costs and overhead costs included as well as operating costs? How are they measured?
17. How have indirect costs (ie, productivity costs, cost of lost time) been identified and estimated?
18.   For variables that are difficult to measure, what method is used to handle this difficulty? Does this method slant the analysis all in favor of one 
intervention in order to bias the analysis against the expected result?
19. was an incremental analysis of costs and consequences of alternatives performed?
20. was allowance made for uncertainty in the estimates of costs and consequences?
21. were adequate sensitivity analyses undertaken, ie, when parameters with high uncertainty were analyzed, did the direction of the results change?
22. If a stochastic sensitivity analysis was applied, are the underlying distribution functions justified?
23. what equity assumptions have been made in the analysis? eg, are QALYs gained by any individual considered equal?
24.   Is the incremental cost-effectiveness ratio estimated for a specific clinical indication that represents the majority of all of its expected use by 
those covered under the programs operated by the decision-makers to whom the report is addressed? Are there other indications, which have 
not been considered which involve a large amount of utilization for which the ratio may be very different?
25.   is there an estimate of the aggregate incremental expenditure required for the decision-makers to whom the study is addressed, to provide 
this product to patients covered by their programs? what is the estimate of aggregate incremental costs? Does this estimate cover all of the 
major indications for use of the product?
26. Did the presentation and discussion of the study results include all issues of concern to users?
To assess transferability:
27. How generalizable and relevant are the results, and validity of the data and model to the relevant jurisdictions and populations?
28. Are there any differences in the following parameters?
    a) Perspective
    b) Preferences
    c) Relative costs
    d) indirect costs
    e) Discount rate
(Continued)ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
100
Goeree et al
Table 4 (Continued)
      f) Technological context
      g) Personnel characteristics
      h) Epidemiological context (including genetic variants)
      i) Factors which influence incidence and prevalence
      j) Demographic context
      k) Life expectancy
      l) Reproduction
      m) Pre- and post intervention care
      n) integration of technology in health care system
      o) incentives
If differences exist, how likely is it that each factor would impact the results? In which direction? Of what magnitude? Taken together, how would they impact the 
results and of what magnitude? Given these potential differences, how would the conclusions likely change in the target setting? Are you able  
to quantify this in any manner?
29. Does the economic evaluation violate your national/regional guidelines for health economic evaluation?
Organizational aspects domain (organizational aspects matrix)
Organizational levels
Organizational aspects dimensions Inter-organizational level Intra-organizational level Health care system
Utilization Type of data and methods of analysis
work processes Data from research (quantitative and qualitative)
Centralization/decentralization Literature reviews
Staff Routine data
Job satisfaction informal knowledge and anecdotes
Communication Judgments
Finances Models
Stakeholders
Organizational aspects domain additional questions:
    1. Are the dimensions assessed relevant for my own research questions? If no, adaptation of organizational aspects data from this report unnecessary.
    2. Are the theories and methods used relevant and reliable ones? A judgment will be necessary here.
    3.   is the analysis transferable (statistically or analytically)? (this will be dependent on the structure of the health care system and similarities of 
units of analysis). A judgment will be necessary here.
    4. Are the results applicable to my context? A judgment will be necessary here.
Source: Turner S, et al. EUnetHTA Adaptation Toolkit work Package 5, v4, 2008.
Abbreviations: HRQoL, health related quality of life; HTA, health technology assessments.
The index was applied to 27 Spanish studies on infec-
tious diseases from the perspective of hypothetical regional 
agency in charge of evaluating health technologies. The 
reason infectious diseases were chosen was because they 
deal with preventive and curative technologies and included 
models with diverse time horizons, which allows the check-
ing off of different aspects included in the proposed index. 
In total, 11 out of 27 studies were deemed not transferable 
as one or more critical factors received a value of 0 and 
were therefore excluded. A global transferability index was 
generated for each transferable study using the arithmetic 
and geometric means (ie, Figure 4; Formula 1) and 2) where 
a = b = 0.5), although the computed values of the index hardly 
showed any variation regardless of the formulation used. 
The transferability of the analyzed studies was relatively 
low; the mean value of the index was 0.534–0.543, with 1 
as the maximum theoretical value. The authors also compared 
the average index value with the average score generated 
using   Boulenger’s10 approach, and the difference was not 
found to be statistically significant.
Summary of approaches
Although there have been seven publications to date on 
alternative systems, processes, or approaches for assessing 
the geographic transferability potential of EEs and HTAs or 
for guiding the conduct of transferring EEs and HTAs across 
jurisdictions, the proposed approaches and the factors used for 
assessing transferability potential have varied substantially 
across these publications. Some of the proposed approaches 
consist simply of a list of a few study quality issues/factors, 
while other proposed approaches have a much more extensive 
list of factors for consideration. Some authors have gone in 
a completely different direction by proposing a sequenced 
flow chart type approach to help guide the process of either 
conducting a transferability study or determining whether a 
primary study in the country of origin is needed.
More common amongst the proposed systems or approaches 
is an assessment of critical criteria for determining transfer-
ability potential first, followed by an assessment based on other 
noncritical factors. Although there is some agreement on what 
these critical and noncritical transferability factors are, there are ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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considerable discrepancies in both the critical and noncritical fac-
tors that have been proposed across the systems and approaches. 
Finally some authors have gone one step further by proposing a 
quantitative score or index to measure transferability potential, 
with a higher score indicating greater transferability likelihood. 
A variant on this approach is a weighting for the index where 
if critical factors are not satisfied, then the index value returns a 
zero indicating the EE or HTA is not transferable.
Discussion
The increasing pressure on health care decision-makers to 
make more efficient use of existing health care resources 
Table 5 Antonanzas’ general and specific transferability index factors
Global index (IT)
General index (IT1)
Critical objective factors:
  1. The relevant parameters needed to calculate the ratio cost/effectiveness are given in the study.
  2. The quality of the study is acceptable:
    a. The study objectives are presented in a clear, specific, and measurable manner.
  b. The variable estimates used in the analysis come from the best available source.
  c. The measurement of cost is appropriate and the methodology for the estimation of quantity and unit costs is clearly described.
  d.   The health outcome measures are based on valid and reliable scales, when available. Otherwise, 
the scales used in the study must be fully justified.
  e.   The economic model (including its structure), study methods, and components of the costs and 
effectiveness are presented in a clear manner.
  f. The conclusions and recommendations for the study are justified and based on the study results.
Noncritical objective factors: The codes as well as description of items are similar to those considered by Boulenger et al
  1. HT1. Is the intervention described in sufficient detail?
  2. HT2. Is the comparator described in sufficient detail?
  3. SE2. Is the country in which the economic study took place clearly specified?
  4. P1. Did the authors correctly state the perspective for the economic analysis?
  5. SP1. is the target population of the health technology clearly stated or can it be inferred by reading the article?
  6. SP3. Does the article provide sufficient detail about the study sample?
  7. E5. Have the principal estimates of effectiveness measures been reported?
  8. E7. Are the results of a statistical analysis of the effectiveness results provided?
  9. B5. Is the level of reporting of benefit data adequate (incremental analysis, statistical analyses)?
10. C1. Are the cost components used in the analysis presented?
11. C5. Are unit price for resources given?
12. C6. Are costs and quantities reported separately?
13. C7. is the price year given?
14. C9. is the currency unit reported?
15. S1. Are quantitative and/or descriptive analyses conducted to explore variability from place to place?
16. O1. Did the authors discuss the generalizability of their results?
Specific index (IT2)
Critical subjective factors:
  1.   The evaluated technology is used in the new health context (This factor will not be taken into account if the economic 
evaluation is carried out to obtain relevant information before the potential use of the technology in the new context).
  2. The comparator is available or used in the new context.
  3. Treatment and comparator data, as well as relevant epidemiological parameters for the technology, are valid in the new context.
  4. The study perspective coincides with that used in the new context.
Noncritical subjective factors:
  1.   Cost components correspond to the medical practice related to the evaluated technology in the original study. 
if medical practice differs in the new context, additional cost components must be taken into account. 
(For example, if in the original study all patients were explored with the CT-Scanner but in the new context, 
both MRi and CT-scanner are used: a new cost component should be included which can be unavailable).
  2. The model connecting variables and parameters can be adapted to the new context.
  3. Life expectancy is similar in both contexts.
  4. Health-status preferences are similar in both contexts. (Applicable to cost/utility analyses).
  5. Productivity measures are similar in both contexts (applicable to cost minimization and cost/benefit analysis).
  6. The evolution of the disease is similar in both contexts.
  7. The applied discount rate is similar in both contexts.
  8. Costs and health effects data are presented in current and discounted units.
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has resulted in a substantial increase in the global demand 
for EEs and HTAs. However, conducting EEs and HTAs 
on every new intervention in every jurisdiction is not only 
unfeasible, but will likely result in a very inefficient use of 
scarce global assessment and evaluation resources. As a 
result, decision-making bodies will increasingly be looking 
at the applicability and feasibility of using EE and HTA 
evidence from other jurisdictions for their own local needs. 
Geographic transferability can be a very promising way 
of making more efficient use of existing assessment and 
evaluation resources and may be the only alternative for 
some jurisdictions who want to follow an evidence-based 
decision-making process but where resources or expertise 
to conduct these assessments are limited.
Most promising from the research to date on geographic 
transferability is the identification of factors that can 
potentially affect transferability. This has led to systems 
and approaches with checklists for assessing and conduct-
ing transferability, and specifically to the development of 
an extensive checklist of critical and noncritical factors in 
determining transferability potential. Although the list of 
factors has varied substantially across publications, some 
patterns have emerged which might form the basis for 
consensus in the development of a future tool, checklist, or 
system. For example, the critical transferability factors that 
have been proposed seem to focus on issues of study quality, 
transparency of methods, the level of reporting of methods 
and results, and the applicability of the treatment comparators 
to the target country. The proposed list of noncritical factors 
has been much more extensive and perhaps future research 
might focus on narrowing or refining this list. More recently, 
indices have been promised to measure transferability 
potential. However, due to the complexities of identifying 
appropriate weights for each of the noncritical factors, it is 
still uncertain whether the assessment and calculation of 
an overall transferability score or index will be practical or 
  useful for transferability considerations in the future.
Researchers need to continue to drive toward consensus 
on developing a list of critical factors that prevent geographic 
transferability and on developing a list of noncritical factors 
that may prevent geographic transferability of EE or HTA 
initiatives across jurisdictions. A consensus will lead to 
good practice guidelines and perhaps eventually to a general 
scoring system or index which could be tailored to each 
jurisdiction based on jurisdiction-specific weights for each 
transferability factor. Whether or not an index measure-
ment approach is practical or useful for decision-makers, 
an essential starting point is consensus across jurisdictions 
regarding the list (eg, checklist) of critical and noncritical 
factors, which are important for determining transferability 
potential.
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Appendix
Search details for PubMed
1.  Chart*[tiab] OR toolkit*[tiab] OR checklist*[tiab] OR 
index*[tiab] OR indices*[tiab] OR methodologic*[tiab] 
OR practice*[tiab] OR guideline*[tiab]
2.  Models, Economic[mh]
3.  Economic evaluation*[tiab]
4.  Technology transfer[mh]
5.  Transferab*[tiab] OR transferrab*[tiab] OR transfer[tiab] 
OR transportable[tiab] OR transportability[tiab] OR 
portable[tiab] OR portability[tiab] OR adapt*[tiab] OR 
generali*[tiab]
6.  1 and (2 or 3) and (4 or 5)
Search details for Ovid MEDLiNE  
and EMBASE
1.  (chart* or toolkit* or checklist* or index* or indices* or 
methodologic* or practice* or guideline*).ti,ab.
2.  Exp Models, Economic/use prmz
3.  Economic evaluation*.ti,ab.
4.  Economic Evaluation/use emez
5.  Technology Transfer/
6.  (transferab* or transferrab* or transfer or transportable 
or transportability or portable or portability or adapt* or 
generali*).ti,ab.
7.  1 and (2 or 3) and (5 or 6 use prmz)
8.  1 and (3 or 4) and (5 or 6 use emez)